AbbVie’s troubled $10B Rova-T cancer drug program takes a sudden turn toward the cliff

The Rova-T problem at AbbVie may be headed toward a full-fledged disaster.

Researchers slammed the brakes on one of their Phase III studies of the $10 billion drug after an independent group of monitors determined that their drug was linked to a shorter overall survival rate than the chemo drug used in the control arm.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->